Literature DB >> 3051402

Identification and assessment of prognostic factors.

S L George1.   

Abstract

Mesh：

Year:  1988        PMID： 3051402

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  15 in total

1.  Multifactorial analysis of survival in primary extremity liposarcoma.

Authors:  H R Chang; J Gaynor; C Tan; S I Hajdu; M F Brennan
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

Review 2.  The impact of surgery on the multidisciplinary treatment of bronchogenic small cell carcinoma (updated review including ongoing studies).

Authors:  W Theuer; O Selawry; K Karrer
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

3.  Is the progress in cancer treatment results adequate or are we confronted with a more or less worldwide stagnation.

Authors:  K Karrer
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

4.  Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients.

Authors:  G Dranitsaris; P Phillips; C Rotstein; A Puodziunas; S Shafran; G Garber; F Smaill; I Salit; M Miller; K Williams; J Conly; J Singer; S Ioannou
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

5.  The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approach.

Authors:  G Dranitsaris; C J Longo; L D Grossman
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

6.  The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy.

Authors:  Mark Vincent; George Dranitsaris; Sunil Verma; Cathy Lau; Pere Gascon; Simon Van Belle; Heinz Ludwig
Journal:  Support Care Cancer       Date:  2006-11-21       Impact factor: 3.603

7.  A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy.

Authors:  G Dranitsaris; P Leung; R Ciotti; A Ortega; M Spinthouri; L Liaropoulos; R Labianca; A Quadri
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

Authors:  G Dranitsaris; M D Vincent; J Yu; L Huang; F Fang; M E Lacouture
Journal:  Ann Oncol       Date:  2012-01-06       Impact factor: 32.976

Review 9.  Statistical aspects of prognostic factor studies in oncology.

Authors:  R Simon; D G Altman
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.

Authors:  George Dranitsaris; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2014-09-13       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.